Skip to content

Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening

Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07546162
Enrollment
280
Registered
2026-04-22
Start date
2026-09-14
Completion date
2026-12-31
Last updated
2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Brief summary

This study collects exhaled breath condensate samples from healthy populations and hyperlipidemic populations, analyzes the characteristics of the exhaled metabolic lipid profile for early identification of people with abnormal blood lipids, verifies the feasibility and accuracy of a new gas detection method for screening abnormal blood lipids, and explores a simple, fast, and non-invasive method for screening abnormal blood lipids.

Interventions

DIAGNOSTIC_TESTLipid Abnormality Mass Spectrometry Screening Model

By analyzing the lipid profile in human breath, explore a simple, fast, and non-invasive method for screening dyslipidemia

Sponsors

Beijing Anzhen Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥ 18 years 2. Voluntarily sign the informed consent form

Exclusion criteria

1. Patients with lung cancer, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or acute respiratory distress syndrome 2. Women during pregnancy or breastfeeding 3. Patients with chronic kidney disease (GFR \<60 ml/min) or liver cirrhosis 4. Individuals unable to cooperate in collecting exhaled breath samples

Design outcomes

Primary

MeasureTime frame
Sensitivity , specificity , Receiver Operating Characteristic Curve and Area Under Curve of mass spectrometry screening model for dyslipidemiaWeek1

Contacts

CONTACTYan Yan
eva3321@sina.com+861064456782

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026